Core Viewpoint - The internal control evaluation report of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. indicates that as of June 30, 2025, the company has maintained effective internal controls over financial reporting and has not identified any significant deficiencies in both financial and non-financial reporting controls [1][2]. Internal Control Objectives - The objective of the internal control system is to ensure legal compliance in management, asset security, accurate financial reporting, and to enhance operational efficiency and effectiveness [2]. Internal Control Evaluation Conclusion - The company concluded that there are no significant deficiencies in financial reporting internal controls as of the evaluation date, and it has maintained effective internal controls in all significant aspects [2][3]. - There are no identified significant deficiencies in non-financial reporting internal controls as of the evaluation date [2][3]. Internal Control Evaluation Scope - The evaluation covered major units, businesses, and high-risk areas based on a risk-oriented principle, including procurement, sales, project management, fund management, asset management, and R&D [3][4]. Internal Control Deficiency Standards - The company has established quantitative and qualitative standards for identifying deficiencies in financial reporting internal controls, with specific thresholds for significant, important, and general deficiencies based on asset and profit amounts [4][5]. - Similar standards are applied for non-financial reporting internal controls, focusing on direct property loss and compliance with laws and regulations [5][6]. Remediation of Internal Control Deficiencies - The company has addressed the majority of identified general deficiencies in financial reporting internal controls during the reporting period [7].

Core Viewpoint - Fosun Pharma reported a decline in revenue for the first half of the year, but a significant increase in net profit, indicating a potential shift in operational efficiency despite lower sales [1] Financial Performance - The company achieved an operating revenue of 19.514 billion yuan, a year-on-year decrease of 4.63% [1] - The net profit attributable to shareholders was 1.702 billion yuan, reflecting a year-on-year growth of 38.96% [1] Strategic Developments - Fosun Pharma's subsidiary granted Sitala rights for the development, production, and commercialization of FXS6837 and related products in a global scope excluding China (including Hong Kong, Macau, and Taiwan) [1] - As part of this licensing arrangement, Fosun Pharma or its designated affiliates can acquire shares of Sitala valued at 5 million USD at zero cost [1]

截至 2025 年 7 月，集团现阶段针对该药品的累计研发投入约为人民币 303 万元(未经审计)。 根据 IQVIA CHPA 最新数据1，2024 年，硫酸长春新碱注射剂于中国大陆境内的销售额约为人民币 2.02 亿元。 该药品为集团(即公司及控股子公司/单位，下同)自主研发的化学药品；拟用于治疗急性白血病，也可联 合其他抗肿瘤药物用于治疗霍奇金淋巴瘤、非霍奇金恶性淋巴瘤、横纹肌肉瘤、神经母细胞瘤和威尔 瘤。 格隆汇8月26日丨复星医药(02196.HK)公布，近日，公司控股子公司吉斯美(武汉)制药有限公司就硫酸 长春新碱注射液(以下简称"该药品")的药品注册申请获国家药品监督管理局受理。 ...

本次合作后，集团仍拥有许可产品于中国（包括港澳台地区）的开发、生产及商业化权利。 FXS6837为集团拥有自主知识产权的小分子抑制剂，拟用于免疫调节领域相关疾病的治疗。截至本公告 日期（即2025年8月26日,下同），FXS6837的相关适应症于中国境内处于II期临床试验阶段。截至2025 年7月，集团现阶段针对该在研药品累计研发投入约为人民币1.20亿元（未经审计）。 格隆汇8月26日丨复星医药(02196.HK)发布公告，2025年8月26日，公司控股子公司复星医药产业与 Sitala达成《许可协议》，由复星医药产业授予Sitala于许可区域（即除中国<包括港澳台地区>外的全球 范围）及领域（即人类、动物疾病的诊断和治疗）开发、生产及商业化FXS6837及含有该活性成分的产 品的权利。同时，基于本次许可之安排，复星医药产业（或其指定关联方）可以零对价获得价值500万 美元的Sitala的股份（预计对Sitala的持股比例不超过10%<全面摊薄后>）。 根据IQVIAMIDASTM最新数据，2024年，全球范围内用于治疗相关疾病的主要药品销售额合计约为38 亿美元。 Sitala成立于2021年5月，注册地 ...

智通财经APP讯，复星医药(02196)发布公告，近日，上海复星医药(集团)股份有限公司(以下简称"公 司")控股子公司吉斯美(武汉)制药有限公司就硫酸长春新碱注射液(以下简称"该药品")的药品注册申请获 国家药品监督管理局受理。 该药品为集团(即公司及控股子公司/单位，下同)自主研发的化学药品;拟用于治疗急性白血病，也可联 合其他抗肿瘤药物用于治疗霍奇金淋巴瘤、非霍奇金恶性淋巴瘤、横纹肌肉瘤、神经母细胞瘤和威尔 瘤。 根据IQVIA CHPA 最新数据，2024年，硫酸长春新碱注射剂于中国境内(不包括港澳台地区)的销售额约 为人民币2.02亿元。 截至2025年7月，集团现阶段针对该药品的累计研发投入约为人民币303万元(未经审计)。 ...

Growth - Shudao Equipment reported a net profit of 10.15 million yuan in the first half of the year, a year-on-year increase of 5972.30% [1] - Aerospace Science and Technology achieved a net profit of 88.97 million yuan, up 2161.91% year-on-year [1] - Tianbao Infrastructure's net profit reached 118 million yuan, growing by 2106.58% year-on-year [1] - Northern Rare Earth reported a net profit of 931 million yuan, an increase of 1951.52% year-on-year [1] - Liugang Co., Ltd. posted a net profit of 36.8 million yuan, up 579.54% year-on-year [1] - Cheng Tian Wei Ye's net profit was 10.88 million yuan, increasing by 562.05% year-on-year [1] - Perfect World reported a net profit of 503 million yuan, a year-on-year increase of 384.52% [1] - Shenghong Technology achieved a net profit of 2.143 billion yuan, up 366.89% year-on-year [1] - Zhongke Magnetic Industry's net profit was 20.90 million yuan, increasing by 271.78% year-on-year [1] - Xinjiang Communications Construction reported a net profit of 255 million yuan, up 255.25% year-on-year [1] - Shennong Group achieved a net profit of 388 million yuan, a year-on-year increase of 212.65% [1] - Daikin Heavy Industries reported a net profit of 547 million yuan, up 214.32% year-on-year [1] - Fostar's net profit was 251 million yuan, increasing by 140.45% year-on-year [1] - Guohua Airlines achieved a net profit of 1.24 billion yuan, up 86.15% year-on-year [1] - China Electric Port reported a net profit of 181 million yuan, increasing by 64.98% year-on-year [1] - Ailisi's net profit was 1.051 billion yuan, up 60.22% year-on-year [1] - Zijin Mining reported a net profit of 23.292 billion yuan, a year-on-year increase of 54.41% [1] - Zhongke Chuangda achieved a net profit of 158 million yuan, up 51.84% year-on-year [1] - Sichuan Gold reported a net profit of 209 million yuan, increasing by 48.41% year-on-year [1] - Dongxing Securities achieved a net profit of 819 million yuan, up 42.12% year-on-year [1] - Fosun Pharma reported a net profit of 1.702 billion yuan, a year-on-year increase of 38.96% [1] - Kotec Power's net profit was 23.99 million yuan, increasing by 35.52% year-on-year [1] - Dongshan Precision reported a net profit of 758 million yuan, up 35.21% year-on-year [1] - Inspur Information achieved a net profit of 799 million yuan, a year-on-year increase of 34.87% [1] - Shenzhen Huaqiang reported a net profit of 236 million yuan, increasing by 33.45% year-on-year [1] - Conch Cement achieved a net profit of 4.368 billion yuan, up 31.34% year-on-year [1] - Jiuzhoutong reported a net profit of 1.446 billion yuan, increasing by 19.7% year-on-year [1] - Aofei Data achieved a net profit of 87.89 million yuan, a year-on-year increase of 16.09% [2] Decline and Loss - Huachang Chemical reported a net profit of 1.09 million yuan, a year-on-year decrease of 97.58% [2] - Meibang Apparel achieved a net profit of 993,030 yuan, down 87.07% year-on-year [2] - Toukeng Life reported a net profit of 275,930 yuan, a decrease of 58.41% year-on-year [2] - BlueFocus reported a net profit of 96.44 million yuan, down 47.33% year-on-year [2] - China Gold achieved a net profit of 31.9 million yuan, a decrease of 46.35% year-on-year [2] - Huaxi Biological reported a net profit of 22.1 million yuan, down 35.38% year-on-year [2] - Zhejiang New Energy achieved a net profit of 29.2 million yuan, down 34.65% year-on-year [2] - Hainan Mining reported a net profit of 28.1 million yuan, a decrease of 30.36% year-on-year [2] - Changying Precision achieved a net profit of 30.6 million yuan, down 29.37% year-on-year [2] - China Duty Free reported a net profit of 2.6 billion yuan, down 20.81% year-on-year [2] - Jiangling Motors achieved a net profit of 73.3 million yuan, down 18.17% year-on-year [2] - Donghua Software reported a net profit of 24.4 million yuan, down 15.78% year-on-year [2] - Hengda New Materials achieved a net profit of 3.4235 million yuan, down 12.68% year-on-year [2] - Yaoji Technology reported a net profit of 25.6 million yuan, down 9.98% year-on-year [2] - Ping An Insurance achieved a net profit of 68.047 billion yuan, down 8.8% year-on-year [2] - China Petroleum reported a net profit of 840.07 billion yuan, down 5.4% year-on-year [2] - 360 reported a net loss of 28.2 million yuan [2] - Electric Wind Power reported a net loss of 27.9 million yuan [2] Losses - Suzhou Keda reported a net loss of 21.7 million yuan [3] - Yuntian Lifa achieved a net loss of 20.6 million yuan [3] - Kosen Technology reported a net loss of 10.5 million yuan [3] - Xinyada reported a net loss of 5.2635 million yuan [3] - Chengfei Integration achieved a net loss of 1.49208 million yuan [3] - China Film reported a net loss of 11 million yuan, turning from profit to loss year-on-year [3]

Core Viewpoint - Fosun Pharma (600196)(02196) announced a licensing agreement with Sitala for the development, production, and commercialization of FXS6837 and related products in a global scope excluding China (including Hong Kong, Macau, and Taiwan) [1] Group 1 - The licensing agreement allows Fosun Pharma's subsidiary to obtain rights for human and animal disease diagnostics and treatments [1] - Fosun Pharma's subsidiary can acquire shares of Sitala valued at $5 million at zero cost based on this licensing arrangement [1] - This collaboration is expected to accelerate the clinical development and commercialization of licensed products globally and expand the group's innovative product portfolio overseas [1]

该药品为集团(即公司及控股子公司/单位，下同)自主研发的化学药品;拟用于治疗急性白血病，也可联 合其他抗肿瘤药物用于治疗霍奇金淋巴瘤、非霍奇金恶性淋巴瘤、横纹肌肉瘤、神经母细胞瘤和威尔 瘤。 截至2025年7月，集团现阶段针对该药品的累计研发投入约为人民币303万元(未经审计)。 根据IQVIA CHPA 最新数据，2024年，硫酸长春新碱注射剂于中国境内(不包括港澳台地区)的销售额约 为人民币2.02亿元。 复星医药（600196）(02196)发布公告，近日，上海复星医药(集团)股份有限公司(以下简称"公司")控股 子公司吉斯美(武汉)制药有限公司就硫酸长春新碱注射液(以下简称"该药品")的药品注册申请获国家药 品监督管理局受理。 ...

Core Viewpoint - Fosun Pharma (02196) has announced a licensing agreement with Sitala for the development, production, and commercialization of FXS6837 and related products in regions outside of China, including Hong Kong, Macau, and Taiwan, which is expected to accelerate clinical development and expand the company's international product portfolio [1] Group 1 - The licensing agreement grants Fosun Pharma's subsidiary the rights to develop and commercialize FXS6837 globally, excluding China [1] - The agreement includes a provision for Fosun Pharma to acquire shares in Sitala valued at $5 million at no cost [1] - This collaboration aims to enhance the clinical development and commercialization process of licensed products on a global scale [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 控股子公司獲藥品註冊申請受理的公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2025 年8 月2 6 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生、潘東輝先生及吳以芳先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生及楊玉成先生；以及本公司之職工董事為嚴佳女士。 ...